Encoded Therapeutics

Home
Our Science
⟵
- Overview
- Genetic Medicines Product Engine
Pipeline & Programs
⟵
Patient
Community
⟵
Healthcare
Professionals
About
News
⟵
- Overview
- Press Releases
- Media Kit
Careers
Contact

Terms of Use
Privacy Policy
Cookie Policy
Social Media Guidelines

Encoded Therapeutics

News
Careers
Contact

Home
Our Science
- Overview
- Genetic Medicines Product Engine
Pipeline &
Programs
Patient
Community
Healthcare
Professionals
About

Optimized human regulatory sequences achieve targeted expression in brain and decreased off-target liver and dorsal root ganglion expression

Post navigation

Previous: The ENVISION Study, an international, prospective natural history study in young children with SCN1A+ Dravet syndrome

Next: The ENVISION Study, an international, prospective natural history study in young children with SCN1A+ Dravet syndrome, 18-month follow-up

Search

Recent Posts

Recent Comments

No comments to show.

Archives

No archives to show.

Categories

No categories

©Copyright 2026 Encoded Therapeutics, Inc.

Terms of Use
Privacy Policy
Cookie Policy

Social Media
Guidelines

You are leaving encoded.com

This link leads outside the Encoded Therapeutics website and we are not responsible for that content.

Yes, I'd like to visit this link. No, I'd like to stay on encoded.com